2026 Q1 -tulosraportti
Vain PDF
116 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 25.8.2025 | ||
2025 Q1 -tulosraportti 28.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
2 päivää sittenLund, Sweden – August 20, 2026 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that a preclinical manuscript characterizing the mechanism of action, broad antitumor efficacy, and ability to elicit antitumor immunity of BI-1808 and BI-1910 has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research. The publication is entitled "Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity" and is available at https://doi.org/10.1158/0008-5472.CAN-26-0274. "This publication provides a comprehensive mechanistic understanding of how BI-1808 and BI-1910 modulate the tumor microenvironment to drive antitumor immunity. It also highlights BioInvent’s leading role in TNFR2 targeting," said Björn Frendéus, Ph.D., Chief Scientific Officer of BioInvent. "The breadth of activity demonstrated across tumor types, notably including poorly CD8+ T cell infiltrated tumors resistant to immune checkpoint blockade, in these preclinical studies is consistent with the clinical signals we are observing with BI-1808 and reinforces our conviction in TNFR2 as a high-value target in cancer immunotherapy." Both anti-TNFR antibodies show potent anti-tumor efficacy across multiple syngeneic tumor models in vivo, can effectively be combined with anti-PD-1, and trigger CD8+ T cell antitumor immunity, albeit by different mechanisms; BI-1808 is a ligand-blocking FcgR-engaging antibody that depletes immunosuppressive Treg cells and reprograms myeloid cells. BI-1910, currently paused due to priority reasons, is a pure agonist antibody that directly co-stimulates T and NK cells through partially FcgR-independent mechanisms. About BI-1808 BI-1808 is a first-in-class drug candidate targeting TNFR2. TNFR2 is upregulated on both immunosuppressive and inflammatory tumor-infiltrating lymphocytes (TILs) and on myeloid cells in the tumor microenvironment, making it a dynamic, promising new target for cancer immunotherapy. BI-1808 is in clinical development for the treatment of T-cell lymphoma and solid tumors. In an ongoing Phase 1/2a study, it has shown both single-agent activity and excellent tolerability, as well as efficacy and a favorable safety profile in combination with pembrolizumab, in solid tumors and T-cell lymphomas About BioInvent BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary n-CoDeR F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. For further information, please contact: Cecilia Hofvander, VP Investor Relations Phone: +46 (0)46 286 85 50 Email: cecilia.hofvander@bioinvent.com
·13.8.Who are upcoming candidates to acquire BI. Yes, as has been written about several times, these BP are probably the main candidates: 1) Merck 2) AstraZeneca 3) Bristol Myers Squibb (BMS) 4) Roche, presumably in that order but I have argued several times for a Japanese Dark Horse; the arrow (mine) also points to Daiichi Sankyo, because they have a unique strategic overlap with BioInvent, which no other Japanese players match. Their focus on ADC-development makes them particularly interested in technologies that can strengthen the antibody-effect — precisely what BI-1206 does via FcγRIIB-inhibition. At the same time, they are actively seeking new immuno-oncological targets, where BioInvent's F.I.R.S.T-platform fits perfectly. It is this combination that makes Daiichi Sankyo the most logical Japanese candidate. But 1 and 2 are almost expected, but I really hope D.S. enters the scene. That would lead to extra board meetings at Merck and Astra, a bit cool. Yes, and if Merck is overtaken, they will have helped finance a product that a competitor can snatch and further develop, a cool thought. If D.S. makes an offer, Merck will almost 100% guarantee come with a counter-offer. Imagine if D.S. subsequently, via other partners, goes in and makes a generic version of Keytruda with BI optimized .. wow
Do you have an educated guess as to why D.S. Merck or A.Z. have not made a bid for the company or at least a project yet?
·15.6.this case has certainly developed in a negative direction is it the fear that they will run out of money they do have a huge cash burn that makes people want to get out last Monday price 29.65 and now 22.5 almost 25 % down bad bad developmentIt is strange. But AstraZeneca is also falling after FDA approval of a drug against prostate cancer today. And AstraZeneca is rock-solid.- 12.6.Summary fra Redeye d.d.: Summary The main lesson we take away from the KOL event is the importance of a clean safety profile. Both BI-1808 in CTCL and the triplet (including BI-1206) in NHL have a class-leading safety profile, while efficacy is up there with the best competing alternatives. While both advanced-line lymphoma treatments and CTCL have several effective treatment modalities, they are all comparatively tough on the patient, which impacts patient quality of life since the diseases are chronic with long survivals. BioInvent is carving out a smart niche focused on treatments with high efficacy and low toxicity, translating into outpatient manageability in the case of lymphoma. Both BI-1808 and BI-1206 are partnering candidates in the near to medium term. BI-1206 is already positioned and ready for partnering in lymphoma, while some additional data are needed for solid indications. A deal in solid tumours will bring in a larger deal, so it can make sense to wait for the NSCLC data that will start coming in in H2. The case is similar for BI-1808, for which the potential is much larger in solid indications, while CTCL represent a be an express route to market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
116 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 2 päivää sittenLund, Sweden – August 20, 2026 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that a preclinical manuscript characterizing the mechanism of action, broad antitumor efficacy, and ability to elicit antitumor immunity of BI-1808 and BI-1910 has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research. The publication is entitled "Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity" and is available at https://doi.org/10.1158/0008-5472.CAN-26-0274. "This publication provides a comprehensive mechanistic understanding of how BI-1808 and BI-1910 modulate the tumor microenvironment to drive antitumor immunity. It also highlights BioInvent’s leading role in TNFR2 targeting," said Björn Frendéus, Ph.D., Chief Scientific Officer of BioInvent. "The breadth of activity demonstrated across tumor types, notably including poorly CD8+ T cell infiltrated tumors resistant to immune checkpoint blockade, in these preclinical studies is consistent with the clinical signals we are observing with BI-1808 and reinforces our conviction in TNFR2 as a high-value target in cancer immunotherapy." Both anti-TNFR antibodies show potent anti-tumor efficacy across multiple syngeneic tumor models in vivo, can effectively be combined with anti-PD-1, and trigger CD8+ T cell antitumor immunity, albeit by different mechanisms; BI-1808 is a ligand-blocking FcgR-engaging antibody that depletes immunosuppressive Treg cells and reprograms myeloid cells. BI-1910, currently paused due to priority reasons, is a pure agonist antibody that directly co-stimulates T and NK cells through partially FcgR-independent mechanisms. About BI-1808 BI-1808 is a first-in-class drug candidate targeting TNFR2. TNFR2 is upregulated on both immunosuppressive and inflammatory tumor-infiltrating lymphocytes (TILs) and on myeloid cells in the tumor microenvironment, making it a dynamic, promising new target for cancer immunotherapy. BI-1808 is in clinical development for the treatment of T-cell lymphoma and solid tumors. In an ongoing Phase 1/2a study, it has shown both single-agent activity and excellent tolerability, as well as efficacy and a favorable safety profile in combination with pembrolizumab, in solid tumors and T-cell lymphomas About BioInvent BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary n-CoDeR F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. For further information, please contact: Cecilia Hofvander, VP Investor Relations Phone: +46 (0)46 286 85 50 Email: cecilia.hofvander@bioinvent.com
- ·13.8.Who are upcoming candidates to acquire BI. Yes, as has been written about several times, these BP are probably the main candidates: 1) Merck 2) AstraZeneca 3) Bristol Myers Squibb (BMS) 4) Roche, presumably in that order but I have argued several times for a Japanese Dark Horse; the arrow (mine) also points to Daiichi Sankyo, because they have a unique strategic overlap with BioInvent, which no other Japanese players match. Their focus on ADC-development makes them particularly interested in technologies that can strengthen the antibody-effect — precisely what BI-1206 does via FcγRIIB-inhibition. At the same time, they are actively seeking new immuno-oncological targets, where BioInvent's F.I.R.S.T-platform fits perfectly. It is this combination that makes Daiichi Sankyo the most logical Japanese candidate. But 1 and 2 are almost expected, but I really hope D.S. enters the scene. That would lead to extra board meetings at Merck and Astra, a bit cool. Yes, and if Merck is overtaken, they will have helped finance a product that a competitor can snatch and further develop, a cool thought. If D.S. makes an offer, Merck will almost 100% guarantee come with a counter-offer. Imagine if D.S. subsequently, via other partners, goes in and makes a generic version of Keytruda with BI optimized .. wowDo you have an educated guess as to why D.S. Merck or A.Z. have not made a bid for the company or at least a project yet?
- ·15.6.this case has certainly developed in a negative direction is it the fear that they will run out of money they do have a huge cash burn that makes people want to get out last Monday price 29.65 and now 22.5 almost 25 % down bad bad developmentIt is strange. But AstraZeneca is also falling after FDA approval of a drug against prostate cancer today. And AstraZeneca is rock-solid.
- 12.6.Summary fra Redeye d.d.: Summary The main lesson we take away from the KOL event is the importance of a clean safety profile. Both BI-1808 in CTCL and the triplet (including BI-1206) in NHL have a class-leading safety profile, while efficacy is up there with the best competing alternatives. While both advanced-line lymphoma treatments and CTCL have several effective treatment modalities, they are all comparatively tough on the patient, which impacts patient quality of life since the diseases are chronic with long survivals. BioInvent is carving out a smart niche focused on treatments with high efficacy and low toxicity, translating into outpatient manageability in the case of lymphoma. Both BI-1808 and BI-1206 are partnering candidates in the near to medium term. BI-1206 is already positioned and ready for partnering in lymphoma, while some additional data are needed for solid indications. A deal in solid tumours will bring in a larger deal, so it can make sense to wait for the NSCLC data that will start coming in in H2. The case is similar for BI-1808, for which the potential is much larger in solid indications, while CTCL represent a be an express route to market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 25.8.2025 | ||
2025 Q1 -tulosraportti 28.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
116 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. | 4 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 25.8.2025 | ||
2025 Q1 -tulosraportti 28.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 2 päivää sittenLund, Sweden – August 20, 2026 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that a preclinical manuscript characterizing the mechanism of action, broad antitumor efficacy, and ability to elicit antitumor immunity of BI-1808 and BI-1910 has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research. The publication is entitled "Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity" and is available at https://doi.org/10.1158/0008-5472.CAN-26-0274. "This publication provides a comprehensive mechanistic understanding of how BI-1808 and BI-1910 modulate the tumor microenvironment to drive antitumor immunity. It also highlights BioInvent’s leading role in TNFR2 targeting," said Björn Frendéus, Ph.D., Chief Scientific Officer of BioInvent. "The breadth of activity demonstrated across tumor types, notably including poorly CD8+ T cell infiltrated tumors resistant to immune checkpoint blockade, in these preclinical studies is consistent with the clinical signals we are observing with BI-1808 and reinforces our conviction in TNFR2 as a high-value target in cancer immunotherapy." Both anti-TNFR antibodies show potent anti-tumor efficacy across multiple syngeneic tumor models in vivo, can effectively be combined with anti-PD-1, and trigger CD8+ T cell antitumor immunity, albeit by different mechanisms; BI-1808 is a ligand-blocking FcgR-engaging antibody that depletes immunosuppressive Treg cells and reprograms myeloid cells. BI-1910, currently paused due to priority reasons, is a pure agonist antibody that directly co-stimulates T and NK cells through partially FcgR-independent mechanisms. About BI-1808 BI-1808 is a first-in-class drug candidate targeting TNFR2. TNFR2 is upregulated on both immunosuppressive and inflammatory tumor-infiltrating lymphocytes (TILs) and on myeloid cells in the tumor microenvironment, making it a dynamic, promising new target for cancer immunotherapy. BI-1808 is in clinical development for the treatment of T-cell lymphoma and solid tumors. In an ongoing Phase 1/2a study, it has shown both single-agent activity and excellent tolerability, as well as efficacy and a favorable safety profile in combination with pembrolizumab, in solid tumors and T-cell lymphomas About BioInvent BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary n-CoDeR F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. For further information, please contact: Cecilia Hofvander, VP Investor Relations Phone: +46 (0)46 286 85 50 Email: cecilia.hofvander@bioinvent.com
- ·13.8.Who are upcoming candidates to acquire BI. Yes, as has been written about several times, these BP are probably the main candidates: 1) Merck 2) AstraZeneca 3) Bristol Myers Squibb (BMS) 4) Roche, presumably in that order but I have argued several times for a Japanese Dark Horse; the arrow (mine) also points to Daiichi Sankyo, because they have a unique strategic overlap with BioInvent, which no other Japanese players match. Their focus on ADC-development makes them particularly interested in technologies that can strengthen the antibody-effect — precisely what BI-1206 does via FcγRIIB-inhibition. At the same time, they are actively seeking new immuno-oncological targets, where BioInvent's F.I.R.S.T-platform fits perfectly. It is this combination that makes Daiichi Sankyo the most logical Japanese candidate. But 1 and 2 are almost expected, but I really hope D.S. enters the scene. That would lead to extra board meetings at Merck and Astra, a bit cool. Yes, and if Merck is overtaken, they will have helped finance a product that a competitor can snatch and further develop, a cool thought. If D.S. makes an offer, Merck will almost 100% guarantee come with a counter-offer. Imagine if D.S. subsequently, via other partners, goes in and makes a generic version of Keytruda with BI optimized .. wowDo you have an educated guess as to why D.S. Merck or A.Z. have not made a bid for the company or at least a project yet?
- ·15.6.this case has certainly developed in a negative direction is it the fear that they will run out of money they do have a huge cash burn that makes people want to get out last Monday price 29.65 and now 22.5 almost 25 % down bad bad developmentIt is strange. But AstraZeneca is also falling after FDA approval of a drug against prostate cancer today. And AstraZeneca is rock-solid.
- 12.6.Summary fra Redeye d.d.: Summary The main lesson we take away from the KOL event is the importance of a clean safety profile. Both BI-1808 in CTCL and the triplet (including BI-1206) in NHL have a class-leading safety profile, while efficacy is up there with the best competing alternatives. While both advanced-line lymphoma treatments and CTCL have several effective treatment modalities, they are all comparatively tough on the patient, which impacts patient quality of life since the diseases are chronic with long survivals. BioInvent is carving out a smart niche focused on treatments with high efficacy and low toxicity, translating into outpatient manageability in the case of lymphoma. Both BI-1808 and BI-1206 are partnering candidates in the near to medium term. BI-1206 is already positioned and ready for partnering in lymphoma, while some additional data are needed for solid indications. A deal in solid tumours will bring in a larger deal, so it can make sense to wait for the NSCLC data that will start coming in in H2. The case is similar for BI-1808, for which the potential is much larger in solid indications, while CTCL represent a be an express route to market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt